Loading patent…
AssigneeDeutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
InventorsFotini Nina Papavasiliou, Hamidreza Hashemi, Gianna Triller, Erec Stebbins, Aubry Miller, Andreas Baumann
Estimating the term…
The invention is based on a platform for vaccination and/or antibody generation. The invention is based on the display of small molecular immunogenic compounds on the coat of variant surface glycoproteins (VSG) on trypanosomes which results in a highly effective immune response when used as a vaccine or in immunization for antibody production. The herein disclosed antigenic particles are applicable for producing antibodies or can be directly used as vaccines for the treatment of various medical conditions. Most preferably the invention relates to the VSG based vaccines specific for dependency causing substances for the treatment of addiction or avoidance of adverse events during drug abuse. Other applications include methods and uses involving the disclosed compounds and compositions for a treatment or prevention of cancer, infectious disease, contagious neurodegenerative diseases, non-communicable disorders (e.g. certain neurodegenerative diseases, allergies) and any condition or industrial use for which an immune response from vaccination or antibody use would be desirable.
An antigenic particle coated with an engineered variant surface glycoprotein (eVSG), wherein the eVSG comprises a VSG linked to an immunogenic compound, wherein the immunogenic compound is a small molecular drug, and which is covalently linked via a linker to the N-terminus of the VSG, wherein the VSG is VSG3 derived from the genome of T. brucei.
An immunogenic engineered VSG (ieVSG) protein, comprising in N- to C-terminal direction:
A system or kit, comprising as components (i) a pre-ieVSG protein and (ii) a compound comprising a sortagging donor sequence, wherein the pre-ieVSG protein comprises in N-to C-terminal direction:
Dependencies are inferred from the claim text.